Compare Equinix Inc (EQIX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Merck & Co., Inc. — how do they compare? Equinix Inc trades at $1,013.18 (market cap $99.77B), while Merck & Co., Inc. trades at $144.77 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 3.5× Equinix Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Merck & Co., Inc. for 98 Days on average.
| EQIX | MRK | |
|---|---|---|
Market Cap | $99.77B | $351.28B |
Volume | 480,425 | 7,969,665 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $156.43 |
52-Week Low | $726.09 | $82.49 |
Typical Hold Time | 110 Days | 98 Days |
Enterprise Value | $120.90B | $398.04B |
Dividend Yield | 2.04% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,016.30, down 1.5% on the day, amid a bullish technical trend and strong analyst support. The stock shows robust revenue growth, with 2025 revenue reaching $9.22 billion and net income margin improving to 14.64%. Recent news highlights accelerating AI-driven demand for data centers, with the company planning $5–7 billion in annual investments. However, high valuation ratios like a P/E of 65.07 and negative net cash flow in 2025 pose concerns.
The outlook for EQIX is positive due to AI infrastructure demand and solid earnings growth, but risks include elevated debt levels and capital expenditure pressures. Wall Street consensus is strongly bullish with a $1,250 price target, though investors should weigh valuation against execution risks in a competitive sector.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
